“…First, not all biomarkers previously associated with ARDS pathogenesis or prognosis were measured. Other biomarkers associated with lung epithelial cell injury (club cell 16, KL-6), 34,35 endothelial injury (soluble intercellular adhesion molecule-1, circulating glycosaminoglycans), 24,30 disordered coagulation and fi brinolysis (plasminogen activator inhibitor-1, protein C, thrombomodulin), 36,37 and infl ammation (IL-1/IL-1-receptor antagonist, soluble tumor necrosis factor receptor 1), 38 to name a few, might further enhance the molecular phenotypes of epithelial and endothelial injury in direct vs indirect ARDS. Second, the larger of the two patient samples used in these analyses came from a secondary analysis of a randomized controlled trial, which excluded many patients at highest risk for mortality from ARDS and was not designed to test the hypothesis under study in this analysis.…”